{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:46Z","timestamp":1790717146396,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Rituximab (RTX) has been the predominant treatment for autoimmune bullous diseases (AIBDs). The objective of this research was to assess the advantages and safety characteristics of RTX treatment in individuals with AIBD. This assessment focused on clinical remission and a reduction in glucocorticosteroid usage, its effect on the titers of autoantibodies targeting desmoglein-1 (DSG-1) and desmoglein-3 (DSG-3), and adverse occurrences during a 12-month follow-up period in a dermatology department within a Central European university context. Materials and Methods: Our case series involved eleven patients, including eight patients with pemphigus vulgaris, two with pemphigus foliaceus, and one with epidermolysis bullosa acquisita. They received a 1 g dose of rituximab, repeated over a two-week interval. Results: The reduction in a prednisone-equivalent dosage after 2, 6, and 12 months following the second RTX infusion was 65.05%, 73.99%, and 76.93%, in that order. The titers of antibodies against DSG-1 exhibited reductions of 43.29%, 75.86%, and 54.02% at 2, 6, and 12 months, respectively. By contrast, the antibody concentrations targeting DSG-3 displayed a decrease of 27.88%, 14.48%, and 5.09% at the corresponding time points. Over the course of the 12-month monitoring period, 18.18% of patients experienced disease relapse, while the remaining individuals achieved either complete or partial remission with minimal or no therapy. Adverse effects were noted in 36.36% of the patient population; they were mild, and no serious adverse effects were reported. Conclusions: RTX represents an efficacious and well-tolerated therapeutic option for the management of AIBD and merits consideration in cases of refractory AIBD. However, further research is imperative to delineate the most optimal dosage, dosing frequency, and total quantity of maintenance infusions required. Additionally, there is a compelling need for studies that explore the impact of RTX on individuals with AIBD who do not exhibit a significant reduction in anti-desmoglein autoantibody levels.<\/jats:p>","DOI":"10.3390\/medicina60020270","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T08:41:43Z","timestamp":1707122503000},"page":"270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4373-6862","authenticated-orcid":false,"given":"Maciej Marek","family":"Spa\u0142ek","sequence":"first","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Ja\u0142owska","sequence":"additional","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-7622","authenticated-orcid":false,"given":"Monika","family":"Bowszyc-Dmochowska","sequence":"additional","affiliation":[{"name":"Cutaneous Histopathology and Immunopathology Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Dmochowski","sequence":"additional","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1103375","DOI":"10.3389\/fimmu.2022.1103375","article-title":"Issues Occupying Our Minds: Nomenclature of Autoimmune Blistering Diseases Requires Updating, Pemphigus Vulgaris Propensity to Affect Areas Adjacent to Natural Body Orifices Unifies Seemingly Diverse Clinical Features of This Disease","volume":"13","author":"Dmochowski","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ja\u0142owska, M., Gornowicz-Porowska, J., Bowszyc-Dmochowska, M., and Dmochowski, M. (2022). Sacral Dimple, Conjunctiva, and Nipple as Less Obvious Pemphigus Vulgaris Locations around Natural Body Orifices: A Report of Three Cases. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102855"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"701809","DOI":"10.3389\/fmed.2021.701809","article-title":"Autoantibody-Specific Signalling in Pemphigus","volume":"8","author":"Schmitt","year":"2021","journal-title":"Front. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1214011","DOI":"10.3389\/fimmu.2023.1214011","article-title":"Case Report: Biological Treatment of Epidermolysis Bullosa Acquisita: Report on Four Cases and Literature Review","volume":"14","author":"Kowalewski","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-Analysis of the Clinical and Immunopathological Characteristics and Treatment Outcomes in Epidermolysis Bullosa Acquisita Patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamadermatol.2022.6250","article-title":"Treatment of Recurrent Epidermolysis Bullosa Acquisita with Tofacitinib","volume":"159","author":"Fan","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000526600","article-title":"Rituximab in Subepidermal Blistering Diseases","volume":"239","author":"Tan","year":"2022","journal-title":"Dermatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5114\/ceji.2021.107028","article-title":"Conceptualization and Validation of an Innovative Direct Immunofluorescence Technique Utilizing Fluorescein Conjugate against IgG + IgG4 for Routinely Diagnosing Autoimmune Bullous Dermatoses","volume":"46","author":"Kaczmarek","year":"2021","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus Statement on Definitions of Disease, End Points, and Therapeutic Response for Pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-Analysis of Different Regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm. Venerol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12016-021-08882-1","article-title":"Comparison of Guidelines for Management of Pemphigus: A Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies","volume":"61","author":"Zhao","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00403-018-1881-1","article-title":"Comparing Early and Late Treatments with Rituximab in Pemphigus Vulgaris: Which One Is Better?","volume":"311","author":"Balighi","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"French study group on autoimmune bullous skin diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial","volume":"20","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"French Study Group on Autoimmune Bullous Diseases. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris","volume":"17","author":"Werth","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3389\/fimmu.2018.01190","article-title":"Non-Desmoglein Antibodies in Patients with Pemphigus Vulgaris","volume":"9","author":"Amber","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","article-title":"Immunogenicity of Rituximab in Patients with Severe Pemphigus","volume":"132","author":"Schmidt","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","article-title":"Inhibitory Human Antichimeric Antibodies to Rituximab in a Patient with Pemphigus","volume":"130","author":"Lunardon","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jid.2019.07.717","article-title":"Autoreactive B Cell Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus Lesions","volume":"140","author":"Zhou","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5114\/dr.2023.130320","article-title":"The cutaneous form of pemphigus vulgaris of the pemphigus chancre type: Clinical and therapeutic implications","volume":"110","author":"Welc","year":"2023","journal-title":"Dermatol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA Testing of Anti\u2013Desmoglein 1 and 3 Antibodies in the Management of Pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12671","DOI":"10.1111\/dth.12671","article-title":"Anti-Desmoglein-1 Levels as Predictor of Prednisolone Tapering in Pemphigus Vulgaris Patients Treated with Rituximab","volume":"31","author":"Balighi","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/jdv.16188","article-title":"Results of the Guideline-based Treatment for Pemphigus: A Single-centre Experience with 84 Cases","volume":"34","author":"Kakuta","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1346-8138.16597","article-title":"Rituximab Therapy for Intractable Pemphigus: A Multicenter, Open-label, Single-arm, Prospective Study of 20 Japanese Patients","volume":"50","author":"Yamagami","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","article-title":"The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy","volume":"13","author":"Zhou","year":"2008","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.celrep.2018.07.093","article-title":"Autoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris","volume":"24","author":"Ellebrecht","year":"2018","journal-title":"Cell Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jid.2021.01.031","article-title":"Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus","volume":"141","author":"Golinski","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e12726","DOI":"10.1111\/dth.12726","article-title":"The Use of Rituximab in Treatment of Epidermolysis Bullosa Acquisita: Three New Cases and a Review of the Literature","volume":"31","author":"Bevans","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e243432","DOI":"10.1136\/bcr-2021-243432","article-title":"Epidermolysis Bullosa Acquisita Treated with Rituximab","volume":"14","author":"Mendes","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38357","DOI":"10.1038\/srep38357","article-title":"T Cells Mediate Autoantibody-Induced Cutaneous Inflammation and Blistering in Epidermolysis Bullosa Acquisita","volume":"6","author":"Bieber","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/jamadermatol.2021.0762","article-title":"Evaluation and Comparison of Clinical and iLaboratory Characteristics of Patients with IGA Epidermolysis Bullosa Acquisita, Linear IGA Bullous Dermatosis, and IGG Epidermolysis Bullosa Acquisita","volume":"157","author":"Becker","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_34","first-page":"779","article-title":"Rituximab for the Treatment of Epidermolysis Bullosa Acquisita: A Large Case Series of 15 Patients","volume":"21","author":"Dasdar","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated in Routine Care with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden","volume":"78","author":"Arkema","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"928621","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","article-title":"Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)","volume":"23","author":"Varley","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_38","unstructured":"Corbaux, C., and Joly, P. (2017). Current Problems in Dermatology, Karger Publishers."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/ejhpharm-2017-001454","article-title":"Tolerance and Safety of Rapid 2-Hour Infusion of Rituximab in Patients with Kidney-Affecting Autoimmune Diseases and Glomerulonephritides: A Single-Centre Experience","volume":"26","author":"Hartinger","year":"2018","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhao, B., Zhou, B., Dong, C., Zhang, R., Xie, D., and Tian, Y. (2021). Lactobacillus Reuteri Alleviates Gastrointestinal Toxicity of Rituximab by Regulating the Proinflammatory T Cells in Vivo. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.645500"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:54:34Z","timestamp":1760104474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,4]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["medicina60020270"],"URL":"https:\/\/doi.org\/10.3390\/medicina60020270","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,4]]}}}